Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is ...

Robert Kramer, former CEO of Emergent BioSolutions, allegedly earned more than $10.1 million by executing trades with ...

Less than six months after cutting 20% of its employees, Vedanta Biosciences has again laid off staff. According to one ...

Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...

Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said ...

The Novo Nordisk Foundation’s funds will go toward supporting early-stage companies working in “human health, planetary ...

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...

Incoming PhRMA Chair Paul Hudson, a day before the White House announcement, pledged to work with the administration as the ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...

2026 is shaping up to be a pivotal year for rare disease drugmakers, with key approvals, filings and readouts lined up for ...

Half of the net proceeds will go to Jazz; it remains unclear who will get the remaining sum. Jazz did not reveal the buyer of ...

It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in ...